Market Overview

'Telehealth' Is Coming To The Mainstream In A Pure-Play Package

'Telehealth' Is Coming To The Mainstream In A Pure-Play Package
Related TDOC
32 Stocks Moving In Friday's Pre-Market Session
Benzinga's Top Upgrades, Downgrades For January 26, 2018
Related CVS
How McKesson Will Stand The Test Of Amazon
10 Most Undervalued Stocks Fund Managers Are Buying
Aceto: Collapsing Generic Drug Pricing Brings Risk Of Covenant Violations (Seeking Alpha)
  • Teladoc Inc (NYSE: TDOC) shares are down 22 percent over the past month, declining steadily since August 10.
  • Leerink Partners’ Steven Wardell initiated coverage of the company with an Outperform rating and a price target of $35.
  • Telehealth has made an entry into the mainstream, Wardell said, citing the reasons as healthcare cost inflation, provider shortages, and healthcare consumerism.

Analyst Steven Wardell said there was a shortage of physicians in the US. Due to this shortage, 62 million Americans had no or inadequate access to primary care, according to the National Association of Community Health Centers. “Telehealth can help address this shortage by making physicians more accessible and filling up their schedules more efficiently,” Wardell wrote.

Employers aiming to control costs are favoring Telehealth. Healthcare benefit costs are growing at a rate faster than inflation and continue to be a major concern area for employers.

Earlier this month, CVS Health Corp (NYSE: CVS) [rated Outperform] announced its plans to partner with Teladoc to offer a wider range of telehealth solutions to customers. “We believe this will generate new consumer demand for telehealth services and feed Teladoc additional volume over time,” Wardell commented.

Leerink Partners estimates the addressable market at over $17 billion for the ambulatory domain alone. Citing Teladoc as “one of the fastest growers in our Digital Health universe,” the analyst said that the company is poised for 60 percent top-line CAGR over the next three years.

Latest Ratings for TDOC

Jan 2018Canaccord GenuityMaintainsBuyBuy
Jan 2018JefferiesInitiates Coverage OnBuy
Dec 2017Deutsche BankInitiates Coverage OnBuy

View More Analyst Ratings for TDOC
View the Latest Analyst Ratings

Posted-In: Analyst Color Biotech Long Ideas Health Care Initiation Top Stories Analyst Ratings Trading Ideas Best of Benzinga


Related Articles (CVS + TDOC)

View Comments and Join the Discussion!